FDA Staff Says Do Not Believe There Is Sufficient Evidence To Support That Any Of The Assessed Biomarkers For Brainstorm Cell Therapeutics' ALS Therapy Is Reasonably Likely To Predict Clinical Benefit
Portfolio Pulse from Benzinga Newsdesk
The FDA staff has expressed skepticism about the efficacy of Brainstorm Cell Therapeutics' ALS therapy, stating that they do not believe there is sufficient evidence to support that any of the assessed biomarkers for the therapy is reasonably likely to predict clinical benefit.
September 25, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The FDA's skepticism about the efficacy of Brainstorm Cell Therapeutics' ALS therapy could negatively impact the company's stock in the short term.
The FDA's opinion carries significant weight in the pharmaceutical industry. Their skepticism about the efficacy of Brainstorm's ALS therapy could lead to a decrease in investor confidence, potentially leading to a drop in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100